

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: FISHMAN11A

In re Application of:)	Confirmation No.: 3649
Pnina FISHMAN)	Art Unit:
)	
Appln. No.: 10/715,823)	Examiner:
)	
Filed: November 19, 2003)	Washington, D.C.
)	
For: A3AR AGONISTS FOR THE)	April 27, 2004
TREATMENT OF...)	
)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop DD
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[XX] before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents,

publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

3. Document(s) _____ is (are) not in the English language. In accordance with §1.98(c), Applicant(s) states:

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. Other information being provided for the examiner's consideration follows:


International Search Report

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.


Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Sheridan Neimark
Reg. No. 20,520

SN:keb
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\C\cohn\FISHMAN11A\pto\Idsform.doc



Substitute for form 1449A/PTO

Complete if Known

(use as many sheets as necessary)

Sheet	1	of
-------	---	----


Application Number
Filing Date
First Named Inventor
Group Art Unit
Examiner Name
Attorney Docket Number

[illegible][illegible]

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

Complete if Known

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BONVINI et al, "Nuclear β -Catenin Displays GSK-3 β - and APC-Independent Proteasome Sensitivity in Melanoma Cells", <u>Biochimica et Biophysica Acta</u> 1495:308-318 (2000)	
		FANG et al, "Phosphorylation and Inactivation of Glycogen Synthase Kinase 3 by Protein Kinase A", <u>Proc Natl Acad Sci</u> 97(22):11960-11965 (2000)	
		FERKLEY et al, "GSK-3: New Thoughts on an Old Enzyme", <u>Developmental Biology</u> 225:471-479 (2000)	
		FISHMAN et al, "Evidence for Involvement of Wnt Signaling Pathway in IB-MECA Mediated Suppression of Melanoma Cells", <u>Oncogene</u> 21:4060-4064 (2002)	
		OLAH et al, "The Role of Receptor Structure in Determining Adenosine Receptor Activity", <u>Pharmacology & Therapeutics</u> 85:55-75 (2000)	
		POULSEN et al, "Adenosine Receptors: New Opportunities for Future Drugs", <u>Bioorganic & Medicinal Chemistry</u> 6:619-641 (1998)	
		SZABÓ et al, "Suppression of Macrophage Inflammatory Protein (MIP)-1 α Production and Collagen-Induced Arthritis by Adenosine Receptor Agonists", <u>British Journal of Pharmacology</u> 125:379-387 (1998)	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.